PolarTIL programming reveals an essential role for TGF-β1 in antitumor memory in human cutaneous malignancies

The human immune system is a vast, internal defense force, constantly patrolling the body to identify and destroy invaders like bacteria and viruses. In recent years, doctors have learned to harness a specific part of this army: white blood cells called T cells. These cells are trained to recognize the unique markings on cancer cells and attack them. One powerful way to use this ability is to take a patient's own cancer cells, find the T cells that have already invaded the tumor, and grow them in a laboratory until there are billions of them. This process, known as adoptive cell therapy, has saved lives, particularly in skin cancers like melanoma. However, a major hurdle remains. When these cells are grown in the lab using standard methods, they often lose their sharp edge. They become exhausted, tired, and less effective at fighting the cancer once they are put back into the patient. Scientists have long sought a way to keep these cells young, energetic, and ready for battle without needing to genetically alter them or use complex, expensive procedures.

A team of researchers at Emory University has found a way to do exactly that by changing the environment in which these cells grow. Instead of relying on the traditional method of feeding the cells a constant, high dose of a growth factor called interleukin-2, they introduced a brief, specific pulse of a different set of chemical signals at the very start of the culture process. They call this new product PolarTIL. The results were striking. In both mouse models and human tissue samples, these reprogrammed cells grew much faster, became more numerous, and retained a distinct, powerful identity that allowed them to destroy tumors far more effectively than the standard cells. Most surprisingly, the researchers discovered that a molecule long thought to be a suppressor of the immune system, called TGF-beta 1, was actually essential for this success. Removing it from the process completely stopped the cells from working, overturning a common assumption in cancer therapy and revealing a new path for treating solid tumors.

The journey to this discovery began with a simple observation about how T cells behave. In the lab, when scientists grow T cells using high doses of interleukin-2, the cells multiply, but they often drift toward a state of exhaustion. They lose their ability to persist in the body and their capacity to kill cancer cells over time. The researchers hypothesized that if they could change the instructions given to the cells right at the beginning of their growth, they could steer them toward a more durable, powerful state. They looked to a specific group of immune cells known as Type-17 cells, which are known in other contexts for their ability to provide long-lasting protection. They designed a cocktail of cytokines—chemical messengers that cells use to talk to one another—to mimic this environment. This cocktail included signals like interleukin-1 beta, interleukin-6, and interleukin-21, along with a single dose of TGF-beta 1.

When they applied this strategy to T cells taken from mouse tumors, the difference was immediate. The cells grown with the new PolarTIL method multiplied to numbers far greater than those grown with the standard high-dose interleukin-2. But the real test was whether these cells could actually cure the disease. The researchers took the expanded cells and injected them back into mice that had aggressive melanoma tumors. The mice treated with the standard cells saw only a slight delay in tumor growth, which was not statistically significant. In contrast, the mice treated with the PolarTIL cells saw their tumors disappear completely. Even more importantly, these mice remained cancer-free for over 100 days. When the researchers challenged these cured mice with a new dose of cancer cells, the animals fought off the new infection without any help, proving that the treatment had created a lasting, systemic immunity. This durability was not just a fluke; the researchers showed that the treatment relied on the continued presence of the transferred cells. When they removed the donor cells from the cured mice, the protection vanished, and the cancer returned.

The team then moved to human tissue to see if this approach would work outside the controlled environment of a mouse. They collected tumor samples from patients with various skin cancers, including melanoma and Merkel cell carcinoma. They split the samples, growing some cells with the standard high-dose interleukin-2 and others with the new PolarTIL strategy. The results mirrored the mouse studies. The PolarTIL cultures produced five times more cells than the standard cultures. They also contained fewer regulatory T cells, which are a type of immune cell that can accidentally turn off the attack on cancer. Instead, the PolarTIL cultures were enriched with cells that had the markers of tissue-resident memory, a state that allows immune cells to live in specific tissues and remain ready to fight. These cells were also more aggressive, killing patient tumor cells much faster in the lab and releasing higher levels of the chemical weapons needed to destroy cancer.

To understand what was happening inside these cells, the researchers looked at their genetic blueprints. They found that the PolarTIL cells were not just a slightly different version of the standard cells; they were a fundamentally different state. The standard cells retained many of the exhausted features they had when they were first taken from the tumor. The PolarTIL cells, however, had shifted their genetic programming. They turned on genes associated with moving through tissues and interacting with other immune cells, while turning off the genes linked to exhaustion. They also showed a preference for expanding the specific clones of cells that were most likely to recognize the tumor, rather than just growing whatever cells happened to be there. This suggested that the brief pulse of signals at the start of the culture was enough to reprogram the entire population, selecting for the most effective fighters.

The most unexpected finding came when the researchers tried to figure out which part of their chemical cocktail was doing the heavy lifting. They systematically removed each ingredient to see what happened. They found that removing most of the signals reduced the number of cells slightly, but the cells still worked. However, when they removed TGF-beta 1, the entire process collapsed. This was a shock because TGF-beta is widely known in cancer research as a molecule that suppresses the immune system and helps tumors hide. In fact, many current therapies are designed to block TGF-beta. Yet, in this specific context, at the very beginning of the cell culture, TGF-beta 1 was indispensable. Without it, the cells failed to develop the tissue-resident markers, they did not persist in the body, and they lost their ability to cure the cancer. The researchers concluded that a brief, early exposure to TGF-beta 1 was not suppressing the cells, but rather teaching them how to become the durable, resident fighters needed for a cure.

This discovery challenges a long-held belief in the field. It suggests that the timing and context of a signal matter more than the signal itself. A molecule that acts as a suppressor in one setting can act as a crucial instructor in another. The PolarTIL cells also showed a shift in how they used energy, relying more on a metabolic pathway that supports long-term survival, unlike the standard cells which relied on a pathway that burns out quickly. Furthermore, these cells showed an increased ability to communicate with other parts of the immune system, such as B cells, which could help coordinate a broader attack on the tumor.

The implications of this work are significant for the future of cancer treatment. The researchers noted that all the chemicals used in their new method are already available in the high-quality formats required for human use, meaning this approach could be translated to patients relatively quickly. By simply changing the initial conditions of the lab culture, they were able to create a product that is more potent, more numerous, and more durable than what is currently available. This offers a new hope for patients with solid tumors who have not responded to other treatments, providing a way to generate a powerful, self-sustaining army of immune cells without the need for complex genetic engineering. The study confirms that the key to better cancer therapies may lie not in adding more complexity, but in understanding the precise, early instructions that guide the immune system toward lasting victory.